The precision medicine concept is both appealing and challenging. We review here the recent findings in the endotype-driven approach for major allergic diseases.
INTRODUCTION
The concept of precision medicine is not new, but advances in genetics, targeted approaches and the growing availability of real-time health data and statistical unbiased models provide an opportunity to turn personalized allergic diseases care into reality.
Precision medicine is anticipated to have a major effect on both clinical practice and the development of new drugs, diagnostic tests and prevention strategies [1,2 & ] . Asthma, atopic dermatitis, allergic rhinitis and chronic rhinosinusitis (CRS) are umbrella terms for different diseases requiring an individualized/stratified approach [3, 4] 
STRATIFIED VERSUS PERSONALIZED MEDICINE AND THE POWER OF KNOWLEDGE NETWORK
Stratified/personalized medicine is at the cutting edge of a new era in healthcare.
Stratified medicine relies on the use of biomarkers to group patients into clusters who are: at risk of developing the disease or evolve with complications; likely to respond better to one therapy over other alternatives; and likely to respond better to preventive measures. Stratified medicine is a step toward personalized medicine, where management is tailored to each individual.
Personalized medicine is the customization of healthcare tailored to the individual and relies mainly on pharmacogenomics. To maximize the potential of this approach, genetic technologies and analysis algorithms need to be adapted to fit clinical needs and to prove cost-effectiveness. More needs to be done for alignment algorithms, qualitycoverage metrics, tailored solutions for paralogous or low-complexity areas of the genome and the adoption of consensus standards for gene variants interpretation.
The knowledge network is the 'brain' of precision medicine, with the informatics power to aggregate all types of information into an information commons, stratify it into 'layers' of distinct data types and then discern patterns and connections within and between layers. This process integrates information across disciplines, from molecular pathways to behavioral information. This new knowledge, in turn, can be visualized and made accessible to researchers and, as clinical decision
DISEASE PHENOTYPES, ENDOTYPES AND BIOMARKERS
The phenotype comprises all the visible properties related to that particular disease from clinical and demographic traits to organ physiology and anatomy (hyperreactivity, barrier function and remodeling), inflammation type (eosinophilic or noneosinophilic), response to treatment, short-term and long-term risk. Phenotypes are frequently overlapping and moreover do not necessarily relate to or give insights into the underlying pathogenic mechanism, which is better described by the endotype [3, 5] . A successful endotype should link the key pathogenic mechanism with the phenotype via biomarkers [6, 7, 8 & ]. New approaches for defining allergic diseases endotypes are available, from targeted immune interventions to more accessible tools for immunophenotyping and new statistical tools [9] . Omics measurements (transcriptomics, proteomics and metabolomics) have been utilized to link the molecular characteristics to visible properties of asthma, atopic dermatitis and CRS [10
There are several drawbacks of the clustering method use for omics data such as longitudinal stability of the clusters, reproducibility in different populations, statistical robustness of the studies and responsiveness to intervention [12] . Research shifted from the investigator-imposed subjective disease clustering (hypothesis driven) toward unbiased, data-driven models using the biomarkers/endotypes approach [9] . Multidimensional endotyping integrating multiple biomarkers with visible properties is recommended for both type-2 and nontype-2 allergic diseases to provide evidence that a certain pathway is the key driver for a given patient [13, 14 & ] (Fig. 1) .
ASTHMA ENDOTYPES
On the basis of cellular profile of induced sputum, several asthma phenotypes are in use today: eosinophilic, neutrophilic, mixed granulocytic and paucigranulocytic [15] . The phenotype of eosinophilic asthma is in the spotlight of the endotype-driven approach and is more precisely defined [16] . ]. Targeting IL-13 alone (lebrikizumab and tralokinumab) failed to provide a consistent effect on asthma exacerbations or lung function [38] [39] [40] . Simultaneous targeting of both IL-4 and IL-13 with dupilumab has better impact on exacerbations and lung function [41] . Other biologics targeting IL-33, thymic stromal lymphopoietin (TSLP) (tezepelumab)
KEY POINTS
The stratified approach for allergic diseases favors the development of new tools to predict and prevent disease, select the best treatment, reduce side-effects for individual patients and to streamlining healthcare in a cost-efficient way.
There are notable barriers in applying stratified medicine in clinical practice because of biomarkers validation and qualification, the dissociated effect of targeted treatment, big data translation into clinical decision algorithms and the integrative analysis of the exposome interference.
Multidimensional endotyping integrating visible properties with multiple biomarkers is recommended for both type 2 and nontype 2 allergic diseases to provide evidence that a certain pathway is the key driver for a given patient.
Significant healthcare system and societal changes are required to achieve the expected targets. ,43]. The effect of tepezelumab on asthma exacerbations was independent of baseline blood eosinophil counts thus supporting the role of non-type 2 mechanisms in the complex type-2 asthma endotype.
Knowledge on the non type-2 asthma endotypes is quite limited, hence its targeted management is lacking completely. Several subendotypes can be postulated such as the activation of the inflammasone pathway [IL-1b/tumor necrosis factor a (TNF-a)/ IL-6/nuclear factor kB], the IL-17 pathway, the mixed T1/T2//T17 endotype and the extensive remodeling subendotype [4, [4] . A few drugs targeting the neutrophilic pathway [CXC chemokine receptors (CXCR2) antagonists, 5-lipoxygenase-activating protein inhibitors, anti-IL-17 and anti-TNF-a) have been developed, although there are currently no active phase 3 trials. Despite the severity of their disease, currently, there are no treatment options for patients with the mixed subendotype. Steroid responsiveness should be tried first possibly using ultrafine particles to control the small airways dysfunction. If steroid unresponsive inhibitors of phosphoinositide 3 kinase, Janus kinase (JAK) or MyD88, key signaling molecules for the T1, T2 and T17 cytokines or a combination of antitype-2 targeted treatment, anti CXCR2 and macrolides deserve further evaluation. For the inflammasome subendotype, targeting the TNF-a pathway (etanercept, infliximab and adalimumab) seems logical although risky because of the notable adverse events. Other targeted interventions have better safety profile: IL-1b (anakinra), IL-6 (tocilizumab and atlizumab), negative antiinflamatory feedback with IL-37, blockade of the costimulatory signal CD80 or CD86-CD28 (Abatacept). Targeting the IL-17 pathway with brodalumab proved to be quite disappointing, probably because of bulk patients selection in the trial. IL-33, Sialic acid-binding Ig-like lectin (Siglec)-9 and High mobility group box 1/ Receptor-for-Advanced-Glycation-End-products are additional potential targets for this subendotype [53, 54] . Paucigranulocytic asthma may not need anti-inflammatory therapy as symptoms may be driven solely by smooth muscle dysfunction or Cluster X FIGURE 1. An unbiased analytical approach is best suited to identify the mechanistic pathways generating endotypes. Multidimensional endotyping integrates visible properties with molecular biomarkers/omics data using statistical methods coupling unsupervised pattern detection with network visualization. The approach facilitates the identification of novel relationships in complex, heterogeneous data sets, allowing for data-driven hypothesis generation that may uncover disease mechanisms. Clusters generated are unbiased by any preexisting hypothesis, but they need to be validated in terms of clinical relevance, stability, reproducibility and responsiveness. The major last step is the translation of the new unbiased data-driven model into relevant tools for clinical practice, research and drug development.
extensive remodeling. Patients with proven airway hypereactivity (AHR) may benefit from mast celldirected therapies or smooth muscle-directed therapies such as long-acting antimuscarinic antagonists (tiotropium and umeclidinium) or bronchial thermoplasty [55] [56] [57] [58] [59] [60] [61] [62] .
ENDOTYPES OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
Similar to asthma, a type 2 and non type-2 endotype can be described for rhinitis. The type 2 endotype is usually attributed to allergic rhinitis. Epithelialderived TSLP, IL-33 and IL-25 can initiate or aggravate a type-2 immune response [4] . Neurogenic and epithelial barrier dysfunction subendotypes are particularly relevant for rhinitis. The neurogenic subendotype is characterized by a relative overexpression of transient receptor potential (TRP) channels on trigeminal nerves and high concentrations of substance P and neurokinins and is related to nasal hyperreactivity (NHR) [4] . Epithelial dysfunction can be primary or secondary to type-2 or type-1 immune response-induced inflammation. It can be divided roughly into the ciliary and barrier dysfunction, with reduced expression of zonula occludens 1 and occludin-1 facilitating subepithelial migration of exogenous immunestimulating molecules [63, 64] . In addition, there are several modulators of endotype expression, such as the environment, microbiome, lifestyle and nasal anatomy.
Less is known about the endotype-driven treatment in allergic rhinitis. In the posthoc analysis, dupilumab significantly improved nasal symptoms in patients with uncontrolled asthma and comorbid persistent allergic rhinitis [65] . In patients with allergic rhinitis, the topical combination azelastine hydrochloride and fluticasone propionate reduced NHR, levels of substance P and b-hexosaminidase [66 & ]. The reduction in b-hexosaminidase levels paralleled increased barrier function and completely reversed eosinophilic inflammation. Repeated applications desensitized sensory neurons expressing TRPA1 and TRPV1 [66 & ]. The distinction between CRS with (CRSwNP) and without nasal polyps (CRSsNP) is insufficient to clearly define subgroups with uniform pathophysiology. Inflammatory processes in CRS are quite complex. Although type-1 cytokines are mostly found in CRSsNP and type-2 cytokines in CRSwNP, there is a substantial overlap, and several other cytokines and biomarkers have also been detected [67, 68] . In addition, there is a wide variation of the endotypes with the geographic region [69] . Anticytokine antibodies were also described, indicating disruption of immune tolerance and mucosal autoimmunity, with the highest levels of anti-IL-5 and anti-IL-17A antibodies in CRSwNP [70] . Serum periostin and the blood eosinophilto-basophil ratio are novel biomarkers for patients with CRSwNP [71] [72] [73] .
ATOPIC DERMATITIS ENDOTYPES
There is a high unmet medical need to define endotypes of atopic dermatitis because of significant implications for risk stratification and targeted therapies. Three main phenotypes of atopic dermatitis are described: non-lesional skin, acute disease flares and chronic remitting relapsing atopic dermatitis [4] . The type-2 endotype is present in all, with a peak in acute disease flares. TH22-driven and TH17-driven inflammation adds to the type-2 endotype in the nonlesional skin, whereas TH22-driven and TH1-driven inflammation is prominent in patients with the chronic form [4, 74, 75] . Epithelial dysfunction is a key mechanism partnering with the dysregulated immune response [4, 76] .
The evaluation of potential biomarkers stretches from noninvasive serum cytokines clusters [77] to expression profiling of skin biopsy specimens [78] and to targeted anti IL-4/IL-13 interventions. Several biomarkers were related to severity of atopic dermatitis, from chemokine (C-C motif) ligand 17 and filagrin mutations to expansion of circulating follicular T helper cells or exaggerated IDO1 expression and activity in Langerhans cells [76, 79, 80] .
The pipeline of targeted topical and systemic therapies for atopic dermatitis is expanding, based on the growing understanding of its mechanisms, and is particularly focused on suppressing the skewed immune activation with beneficial clinical effects on the overall skin condition, as well as on comorbidities such as asthma or food allergy. Additional effect on pruritus and the disturbed microbiome has other potential advantages. Robust evidence of the efficacy of novel immunologic approaches in atopic dermatitis is available for dupilumab. Two short (16 weeks) phase III trials showed a significant effect of dupilumab on signs and symptoms of atopic dermatitis [81] . Two long-term trials (1 year) confirmed its efficacy with acceptable safety [82, 83] . Other targeted interventions are under investigation: topical phosphodiesterase 4 (PDE4) and JAK inhibitors, biologics inhibiting type-2/ TH22/TH17 cytokines (lebrikizumab, tralokinumab, nemolizumab and ustekinumab), orally administered small-molecule inhibitors targeting thymus and activation-regulated chemokine, PDE4, the histamine 4 receptor and JAK or specifically itching (neurokinin 1 receptor inhibitors) [84, 85] .
CHALLENGES FOR THE STRATIFIED MEDICINE APPROACH FOR ALLERGIC DISEASE
The majority of biomarkers described for allergic diseases predict treatment response and very few forecast disease risk and progression. Most of the biomarkers are suitable only for research setting, few of them are validated and none of them is qualified [9] . Biomarkers are highly variable across age, disease severity and in time; thus, longitudinal evaluation of the biomarkers and the stability of a given endotype is essential. For type-2 asthma, an exhaustive list of biomarkers is described [8 & ], which is not applicable at the point of care. Oversimplification by choosing the noninvasive and easily measurable biomarkers [4] runs into the problem that same biomarkers (e.g. blood eosinophils) predict the efficacy of all type-2 targeted interventions.
Same target/biomarker might not show consistent validity. After successful reduction of asthma exacerbations with omalizumab, targeting the IgE pathway with a different monoclonal antibody failed to reach a meaningful outcome [86] . Lebrikizumab failed in phase 3 studies [39] . In severe asthma, periostin was associated with lung eosinophilia, serum IgE and blood eosinophilia [87, 88] ; however, in moderate asthma, periostin failed to associate with type-2 biomarkers even after stratification for serum IgE [21] . Periostin is not associated with asthma control and the ability to predict the presence of eosinophilic asthma was modest compared to blood eosinophils [89] .
There are several factors continuously modulating the disease endotype, from genetics and epigenetics to anatomical factors, exposome and microbiome, metabolic pathways and psychological factor [9, 90] .
The dissociated effect with intraindividual responses to a targeted approach was described several years ago [6] . The meta-analysis of mepolizumab trials confirmed this observation showing a good effect of mepolizumab on exacerbations and FEV1 but no effect on rescue medication use and AHR [30] . Thus, the biomarker/endotype approach is not always paralleling the outcome driven-approach.
The eligibility of patients for targeted treatment in real life is yet to be proven given the low applicability of the stringent criteria of randomized clinical trials to the general population. In a real-life study, 0% of patients were eligible for mepolizumab, 31-41% for omalizumab and 5% for reslizumab [91] .
Precision medicine implies capacity to handle vast amounts of data. These databases need to prove clinical and research utility to justify investment. Big data translation into clinical decision algorithms and the integrative analysis of the exposome interference prove to be particularly difficult.
The present healthcare system is clearly not ready for stratified medicine. A significant shift in the doctor-patient relationship is expected with the well-informed patient advocating for its own care and connected in real time with the healthcare provider that is provided with personalized information from patient portals. Rapid learning systems shape vast amounts of 'real-world' data unbiased by any preselection criteria into real-time clinical decision support at the point of care leading to harmonized care based on quality criteria. Upskilling the healthcare providers and the bioinformaticians who can ensure that the data are available, high quality and well managed is further needed [92] . Regulatory approval of the combinations of drugs and diagnostic tests is also complicated.
CONCLUSION
The endotype-driven approach made some small but decisive steps in the management of type-2 asthma, atopic dermatitis and CRS. More research is urgently needed for non type-2 asthma, allergic rhinitis, anaphylaxis, food and drug allergy and allergen immunotherapy. Addition of new targets such as the epithelial barrier, the airway smooth muscle, the innate immune cells and the epigenetic modifications will certainly prove rewarding in the near future.
Key-points for moving the field forward are increased usage of the concept of multidimensional endoyping to profile the complex endotypes/subendotypes type-2 and nontype 2 allergic diseases combined with a revised disease nomenclature based on endotypes. The systems medicine approach complemented by health-information technology is a must although hampered at present by the difficulty in translating big data. Financial support and sponsorship None.
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